250 related articles for article (PubMed ID: 28045934)
21. Artificial intelligence enabled parabolic response surface platform identifies ultra-rapid near-universal TB drug treatment regimens comprising approved drugs.
Clemens DL; Lee BY; Silva A; Dillon BJ; Masleša-Galić S; Nava S; Ding X; Ho CM; Horwitz MA
PLoS One; 2019; 14(5):e0215607. PubMed ID: 31075149
[TBL] [Abstract][Full Text] [Related]
22. The impact of improved detection and treatment of isoniazid resistant tuberculosis on prevalence of multi-drug resistant tuberculosis: A modelling study.
Romanowski K; Campbell JR; Oxlade O; Fregonese F; Menzies D; Johnston JC
PLoS One; 2019; 14(1):e0211355. PubMed ID: 30677101
[TBL] [Abstract][Full Text] [Related]
23. Population-level impact of same-day microscopy and Xpert MTB/RIF for tuberculosis diagnosis in Africa.
Dowdy DW; Davis JL; den Boon S; Walter ND; Katamba A; Cattamanchi A
PLoS One; 2013; 8(8):e70485. PubMed ID: 23950942
[TBL] [Abstract][Full Text] [Related]
24. Modelling the global burden of drug-resistant tuberculosis avertable by a post-exposure vaccine.
Fu H; Lewnard JA; Frost I; Laxminarayan R; Arinaminpathy N
Nat Commun; 2021 Jan; 12(1):424. PubMed ID: 33462224
[TBL] [Abstract][Full Text] [Related]
25. Do we need to detect isoniazid resistance in addition to rifampicin resistance in diagnostic tests for tuberculosis?
Denkinger CM; Pai M; Dowdy DW
PLoS One; 2014; 9(1):e84197. PubMed ID: 24404155
[TBL] [Abstract][Full Text] [Related]
26. The importance of implementation strategy in scaling up Xpert MTB/RIF for diagnosis of tuberculosis in the Indian health-care system: a transmission model.
Salje H; Andrews JR; Deo S; Satyanarayana S; Sun AY; Pai M; Dowdy DW
PLoS Med; 2014 Jul; 11(7):e1001674. PubMed ID: 25025235
[TBL] [Abstract][Full Text] [Related]
27. Expected effects of adopting a 9 month regimen for multidrug-resistant tuberculosis: a population modelling analysis.
Kendall EA; Fojo AT; Dowdy DW
Lancet Respir Med; 2017 Mar; 5(3):191-199. PubMed ID: 27989591
[TBL] [Abstract][Full Text] [Related]
28. Treatment of latent tuberculosis infection in HIV infected persons.
Akolo C; Adetifa I; Shepperd S; Volmink J
Cochrane Database Syst Rev; 2010 Jan; 2010(1):CD000171. PubMed ID: 20091503
[TBL] [Abstract][Full Text] [Related]
29. The Impact and Cost-Effectiveness of a Four-Month Regimen for First-Line Treatment of Active Tuberculosis in South Africa.
Knight GM; Gomez GB; Dodd PJ; Dowdy D; Zwerling A; Wells WA; Cobelens F; Vassall A; White RG
PLoS One; 2015; 10(12):e0145796. PubMed ID: 26717007
[TBL] [Abstract][Full Text] [Related]
30. Estimating the Impact of Reducing Under-Nutrition on the Tuberculosis Epidemic in the Central Eastern States of India: A Dynamic Modeling Study.
Oxlade O; Huang CC; Murray M
PLoS One; 2015; 10(6):e0128187. PubMed ID: 26046649
[TBL] [Abstract][Full Text] [Related]
31. Long-term impact of the adoption of bedaquiline-containing regimens on the burden of drug-resistant tuberculosis in China.
Agnarson AM; Wang XC; Potluri R; Bhandari H; Dhir A; Kambili C; Metz L
BMC Infect Dis; 2020 Feb; 20(1):113. PubMed ID: 32041542
[TBL] [Abstract][Full Text] [Related]
32. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
33. 4-month moxifloxacin containing regimens in the treatment of patients with sputum-positive pulmonary tuberculosis in South India - a randomised clinical trial.
Velayutham B; Jawahar MS; Nair D; Navaneethapandian P; Ponnuraja C; Chandrasekaran K; Narayan Sivaramakrishnan G; Makesh Kumar M; Paul Kumaran P; Ramesh Kumar S; Baskaran D; Bella Devaleenal D; Sirasanambati DR; Vasantha M; Palaniyandi P; Ramachandran G; Uma Devi KR; Elizabeth Hannah L; Sekar G; Radhakrishnan A; Kalaiselvi D; Dhanalakshmi A; Thiruvalluvan E; Raja Sakthivel M; Mahilmaran A; Sridhar R; Jayabal L; Rathinam P; Angamuthu P; Soorappa Ponnusamy K; Venkatesan P; Natrajan M; Prasad Tripathy S; Swaminathan S
Trop Med Int Health; 2020 Apr; 25(4):483-495. PubMed ID: 31944502
[TBL] [Abstract][Full Text] [Related]
34. Principles of chemotherapy for tuberculosis in national tuberculosis programmes of low- and middle-income countries.
Chiang CY; Lin CJ
Indian J Tuberc; 2020 Dec; 67(4S):S16-S22. PubMed ID: 33308663
[TBL] [Abstract][Full Text] [Related]
35. Clinical Impact of Rapid Drug Susceptibility Testing to Accompany Fluoroquinolone-Containing Universal Tuberculosis Regimens: A Markov Model.
Kendall EA; Malhotra S; Cook-Scalise S; Dowdy DW; Denkinger CM
Clin Infect Dis; 2020 Dec; 71(11):2889-2896. PubMed ID: 31813958
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of a six-month versus a 36-month regimen for prevention of tuberculosis in HIV-infected persons in India: a randomized clinical trial.
Swaminathan S; Menon PA; Gopalan N; Perumal V; Santhanakrishnan RK; Ramachandran R; Chinnaiyan P; Iliayas S; Chandrasekaran P; Navaneethapandian PD; Elangovan T; Pho MT; Wares F; Paranji Ramaiyengar N
PLoS One; 2012; 7(12):e47400. PubMed ID: 23251327
[TBL] [Abstract][Full Text] [Related]
37. Treatment outcomes for isoniazid-resistant tuberculosis under program conditions in British Columbia, Canada.
Romanowski K; Chiang LY; Roth DZ; Krajden M; Tang P; Cook VJ; Johnston JC
BMC Infect Dis; 2017 Sep; 17(1):604. PubMed ID: 28870175
[TBL] [Abstract][Full Text] [Related]
38. The point of view of a high prevalence country: Malawi.
Nyangulu DS
Bull Int Union Tuberc Lung Dis; 1991 Dec; 66(4):173-4. PubMed ID: 1687509
[TBL] [Abstract][Full Text] [Related]
39. Shortened Tuberculosis Treatment for People with HIV in South Africa. A Model-based Evaluation and Cost-effectiveness Analysis.
Reddy KP; Horsburgh CR; Wood R; Fields NF; Girouard MP; Costantini S; Hou T; Freedberg KA; Walensky RP
Ann Am Thorac Soc; 2020 Feb; 17(2):202-211. PubMed ID: 31689133
[No Abstract] [Full Text] [Related]
40. Global guidelines for treatment of tuberculosis among persons living with HIV: unresolved issues.
Kumar A; Kumar AM; Gupta D; Kanchar A; Mohammed S; Srinath S; Tripathy S; Rajasekaran S; Chan PL; Swaminathan S; Dewan PK
Int J Tuberc Lung Dis; 2012 May; 16(5):573-8. PubMed ID: 22507931
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
